biostudies-literatureMatson SMNIGMS NIH HHSNIGMS861-869https://www.ebi.ac.uk/biostudies/studies/S-EPMC10107057biostudies-literatureUnknown163(4)<h4>Background</h4>Rheumatoid arthritis (RA)-associated interstitial lung disease (ILD) is common in patients with RA and leads to significant morbidity and mortality. No randomized, placebo-controlled data are available that support the role of immunosuppression to treat RA-associated ILD, despite being widely used in clinical practice.<h4>Research question</h4>How does immunosuppression impact pulmonary function trajectory in a multisite retrospective cohort of patients with RA-associated ILD?<h4>Study design and methods</h4>Patients with RA who started treatment for ILD with mycophenolate, azathioprine, or rituximab were identified retrospectively from five ILD centers. Change in lung function before and after treatment was analyzed using a linear spline mixed-effect model with random iChestTreatment Outcomes for Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Real-World, Multisite Study of the Impact of Immunosuppression on Pulmonary Function Trajectory.PMC10107057P20 GM130423Baqir MDiaz FJDonatelli JMBoente RDPope KHamblin MBMatson SMLee JSMathai SKMarll MKent JMoua TIannazzo NSDemoruelle MKWalker CMRyu JHDai JfalseTreatment Outcomes for Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Real-World, Multisite Study of the Impact of Immunosuppression on Pulmonary Function Trajectory.<h4>Background</h4>Rheumatoid arthritis (RA)-associated interstitial lung disease (ILD) is common in patients with RA and leads to significant morbidity and mortality. No randomized, placebo-controlled data are available that support the role of immunosuppression to treat RA-associated ILD, despite being widely used in clinical practice.<h4>Research question</h4>How does immunosuppression impact pulmonary function trajectory in a multisite retrospective cohort of patients with RA-associated ILD?<h4>Study design and methods</h4>Patients with RA who started treatment for ILD with mycophenolate, azathioprine, or rituximab were identified retrospectively from five ILD centers. Change in lung function before and after treatment was analyzed using a linear spline mixed-effect model with random i2023-01-01T00:00:00Z2023 Apr2025-06-01T12:09:57.297Z2024-11-20T15:17:22.069ZS-EPMC101070573647041610.1016/j.chest.2022.11.035